Cannabinoids and cognition in Parkinson’s disease: Insights from animal models and emerging clinical evidence.
| Journal | Neuroscience |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Parkinson’s disease (PD) is a progressive, multisystem neurodegenerative disorder characterized not only by motor impairments but also by a broad spectrum of debilitating non-motor symptoms, including cognitive decline. The cognitive function depends on neuronal plasticity, which is tightly regulated by multiple signaling systems, among which the endocannabinoid system (ECS) plays a significant role. Over the past three decades, substantial evidence has accumulated regarding how endogenous cannabinoids, plant-derived cannabinoids, and pharmacological modulators of ECS signaling influence synaptic plasticity, neuronal excitability, and neuroinflammation – processes that are critical in PD pathophysiology. This narrative review synthesizes experimental and clinical evidence on the effects of cannabinoid compounds on cognition in preclinical PD models and patients. Available clinical data are limited, heterogeneous, and often underpowered, with cognition frequently assessed as a secondary
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Does Parkinson’s disease affect thinking, not just movement?
Yes. The review describes Parkinson’s disease as a progressive, multisystem neurodegenerative disorder. It is characterized not only by motor impairments but also by a broad spectrum of debilitating non-motor symptoms, and cognitive decline is one of those non-motor symptoms.
How is the endocannabinoid system linked to cognition?
According to the review, cognitive function depends on neuronal plasticity. This plasticity is tightly regulated by multiple signaling systems, and the endocannabinoid system is described as playing a significant role among them. The review draws on this link in examining how cannabinoid compounds may affect cognition in Parkinson’s disease.
What kinds of cannabinoid research does this Parkinson’s review cover?
It is a narrative review of experimental and clinical evidence on how cannabinoid compounds affect cognition in preclinical Parkinson’s models and in patients. Over three decades, research has examined how endogenous cannabinoids, plant-derived cannabinoids, and drugs that modulate endocannabinoid signaling influence synaptic plasticity, neuronal excitability, and neuroinflammation, processes critical in Parkinson’s disease.
Is there strong clinical evidence that cannabinoids help cognition in Parkinson’s?
No. The review describes the available clinical data as limited, heterogeneous, and often underpowered. In many of these studies, cognition was assessed as a secondary measure rather than the main focus. The review covers both preclinical Parkinson’s models and patients, but the clinical side of this evidence remains limited.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
